Codexis shares surge 35.43% intraday after Q4 2025 earnings beat, strong 2026 revenue guidance, and Merck tech transfer agreement.
ByAinvest
Thursday, Mar 12, 2026 10:23 am ET1min read
CDXS--
Codexis surged 35.43% intraday, driven by Q4 2025 results exceeding expectations (revenue of $38.9M, up 81% YoY, surpassing analyst estimates of $36.82M, and net profit of $9.6M vs. a $10.4M loss in 2024), a 2026 revenue guidance of $72–76M (above market forecasts of $70.8M), and progress in core operations, including a $37.8M technology transfer agreement with Merck and advancements in RNAi applications via its ECO Synthesis platform.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet